Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 59

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 59
---
 and modifying genetic elements. By using a set of computational and advanced AI tools and end-to-end discovery and development pipelines, GeneRator AI identifies genomic elements of interest that can be then applied through genome editing, genetic engineering, as biomarkers, or through additional applications.
 
Validation and screening systems
 
Our experimental technologies include bioassays as well as screening and validation pipelines (i.e., sets of bioassays organized in a cascade of tests). They relate to diverse scientific fields, including molecular biology and biochemistry, microbiology plant tissue culture and plant pathology, in laboratories, greenhouses, and field settings. All processes are accompanied by precise data gathering and are coordinated by pipeline management and quality assurance.
 
Our validation and screening systems support three key aspects of our research and development approach: first, generating data sets to enable the development and proof of concept of tailored computational modules and their prediction performance evaluation; second, transforming computational-based recommendations to a physical entity output; and third, validating and screening selected product candidates by the relevant scientific teams.
 

Major Occurrences and Developments
 
The following are major occurrences and developments in the Company throughout 2024 and through the date of this Annual Report, reflecting advancement in all areas of activity:
Evogene
 

•   ATM (March 2024) – Evogene entered into a Sales Agreement with Lake Street Capital Markets, LLC, pursuant to which we may offer
       and sell, from time to time, our ordinary shares, in an “at the market offering”, for an aggregate offering price of up to  
                                                             $7.3 million.                                                         
-----------------------------------------------------------------------------------------------------------------------------------

•   Established a new subsidiary (April 2024) – Evogene and TKH, established Finally, specializing in protein production in plants
                                                        for the food industry.                                                    
----------------------------------------------------------------------------------------------------------------------------------

•   Collaboration (October 2024) - Evogene announced collaboration with Google Cloud to develop a foundation model for generative small
                     molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation.                
---------------------------------------------------------------------------------------------------------------------------------------

•      Registered Direct Offering and Private Placement (August 2024)- On August 23, 2024, Evogene entered into a definitive securities   
    purchase agreement, or the Securities Purchase Agreement, with an institutional investor, or the Investor, pursuant to which we agreed
    to issue and sell to such investors in a registered direct offering, or the 2024 Offering, (i) 265,000 ordinary shares, par value NIS